Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ionis Licenses Centronuclear Myopathy Drug to Dynacure | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Ionis Licenses Centronuclear Myopathy Drug to Dynacure

The agreement accelerates the potential finding of a new treatment for patients with CNM

By: Betsy Louda

, Contract Pharma

Ionis Pharmaceuticals, Inc. has licensed IONIS-DNM2-2.5Rx, a drug that treats centronuclear myopathy (CNM), to Dynacure. 

 

Ionis earned a $5 million license fee in the form of Dynacure equity from the agreement, and is eligible to receive additional cash or equity of up to more than $205 million in milestone payments. They also now have the eligibility to receive royalties on future product sales of the drug.

 

The collaboration also means that Dynacure will now assume all development and commercialization responsibilities for the program. 

 

“This development puts us one step closer to potentially finding a new treatment for patients suffering with CNM, a devastating disease with no adequate treatments” said Stephane van Rooijen, chief executive officer of Dynacure.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters